Evaluation the effect of coenzyme Q10 on blood inflammatory and oxidant factors and beta-secretase activity levels in diabetic retinopathy patients

Evaluation the effect of coenzyme Q10 and placebo on blood inflammatory and oxidant factors and beta-secretase activity levels in diabetic retinopathy patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160524028046N2

Enrollment

Registered

2022-03-18

Start date

2023-04-04

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Retinopathy. Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy

Interventions

Intervention 1: Intervention group:Patients will be treated with Coenzyme Q10 soft gel prepared from jalinus Pharmaceutical Company (Tehran-Iran),orally (200mg), daily for 120 days. Intervention 2: C

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: diabetic retinopathy patients

Exclusion criteria

Exclusion criteria: Other effective ocular disease and neurological diseases such as Alzheimer's and MS

Design outcomes

Primary

Measure	Time frame
Inflammatory/Anti Inflammatory factors. Timepoint: pre and post Treatment. Method of measurement: Elisa Kits.;Oxidant /Anti Oxidant Factors. Timepoint: pre and post Treatment. Method of measurement: Elisa kits.;Serum Beta secretase activity. Timepoint: pre and post Treatment. Method of measurement: Elisa Kit.	—

Secondary

Measure	Time frame
Blood pressure. Timepoint: pre and post Treatment. Method of measurement: Standard Barometer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbdolrahman Sarihi

Hamedan University of Medical Sciences

sarihi@umsha.ac.ir+98 81 3131 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026